Literature DB >> 29079537

Enzyme decorated drug carriers: Targeted swords to cleave and overcome the mucus barrier.

Claudia Menzel1, Andreas Bernkop-Schnürch2.   

Abstract

The use of mucus permeating drug carrier systems being able to overcome the mucus barrier can lead to a remarkable enhancement in bioavailability. One promising approach is the design of mucolytic enzyme decorated carrier systems (MECS). These systems include micro- and nanoparticles as well as self-emulsifying drug delivery systems (SEDDS) decorated with mucin cleaving enzymes such as papain (PAP) or bromelain (BRO). MECS are able to cross the mucus barrier in a comparatively efficient manner by cleaving mucus substructures in front of them on their way to the epithelium. Thereby these enzymes hydrolyze peptide bonds of mucus glycoproteins forming tiny holes or passages through the mucus. In various in vitro and in vivo studies MECS proved to be superior in their mucus permeating properties over nanocarriers without enzyme decoration. PAP decorated nanoparticles, for instance, remained 3h after oral administration to an even 2.5-fold higher extend in rat small intestine than the corresponding undecorated nanoparticles permeating the intestinal mucus gel layer to a much lower degree. As MECS break up the mucus network only locally without destroying its overall protective barrier function, even long term treatments with such systems seem feasible. Within this review article we address different drug carrier systems decorated with various types of enzymes, their particular pros and cons and potential applications.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29079537     DOI: 10.1016/j.addr.2017.10.004

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  7 in total

Review 1.  Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems.

Authors:  Daniélle van Staden; Richard K Haynes; Joe M Viljoen
Journal:  Antibiotics (Basel)       Date:  2022-06-15

Review 2.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

3.  Improving The Oral Absorption Of Nintedanib By A Self-Microemulsion Drug Delivery System: Preparation And In Vitro/In Vivo Evaluation.

Authors:  Hongfei Liu; Jiaao Mei; Ying Xu; Lei Tang; Daquan Chen; Yating Zhu; Shuguang Huang; Thomas J Webster; Hui Ding
Journal:  Int J Nanomedicine       Date:  2019-11-06

4.  Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer.

Authors:  Ashok K Dilly; Brendon D Honick; Robin Frederick; Anuleka Elapavaluru; Sachin Velankar; Hima Makala; T Kevin Hitchens; Lesley M Foley; Jianxia Guo; Jan H Beumer; Lora Heather Rigatti; Yong J Lee; David L Bartlett; Haroon A Choudry
Journal:  Transl Res       Date:  2020-10-22       Impact factor: 7.012

5.  Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting.

Authors:  Rokaya O Amara; Alyaa A Ramadan; Riham M El-Moslemany; Maha M Eissa; Mervat Z El-Azzouni; Labiba K El-Khordagui
Journal:  Int J Nanomedicine       Date:  2018-08-06

6.  Optical catapulting of microspheres in mucus models-toward overcoming the mucus biobarrier.

Authors:  Ada-Ioana Bunea; Manto Chouliara; Stine Harloff-Helleberg; Andrew R Bañas; Einstom L Engay; Jesper Glückstad
Journal:  J Biomed Opt       Date:  2019-03       Impact factor: 3.170

7.  Development of Self-Emulsifying Drug Delivery Systems (SEDDSs) Displaying Enhanced Permeation of the Intestinal Mucus Following Sustained Release of Prototype Thiol-Based Mucolytic Agent Load.

Authors:  Ahmad Malkawi; Nasr Alrabadi; Razan Haddad; Azhar Malkawi; Khaled Khaled; Airemwen Collins Ovenseri
Journal:  Molecules       Date:  2022-07-19       Impact factor: 4.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.